.Attribute Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA study, after a mean consequence of 11 months, individuals along with metastatic intestinal cysts that got biomarker-matched treatments based on flowing lump DNA profiling revealed a greater professional advantage than those getting unparalleled treatment.